Jun 03, 2024 12:44 pm EDT OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma
Sep 22, 2022 8:57 am EDT Team Arnav Foundation Partners with OS Therapies Supporting the Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma
Jan 27, 2022 8:43 am EST OS Therapies Announces Nationwide Open Enrollment of Remaining 36 to 42 Patients in Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma
Nov 03, 2021 8:57 am EDT OS Therapies Receives Rare Pediatric Disease Designation (RDD) in Osteosarcoma for OST-HER2 (Listeria monocytogenes)
Oct 22, 2021 8:33 am EDT OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2 (Listeria monocytogenes) in Recurred, Resected Osteosarcoma
Jun 23, 2021 8:44 am EDT Children's Cancer Research Fund Supports AOST-2121 PhIIb Clinical Trial in Recurred, Resected Osteosarcoma
Jan 26, 2021 8:49 am EST OS Therapies Receives Trial Approval From Children's Oncology Group for AOST2121 / OST31-164-01 An Open-Label Phase 2 Study of Maintenance Therapy With OST31-164 After Resection of Recurrent Osteosarcoma
Nov 17, 2020 8:37 am EST OS Therapies Acquires All Indications for OST-HER2 (Listeria monocytogenes) in Solid Tumors, Including Canines
Oct 15, 2020 8:56 am EDT FDA Transfers Investigational New Drug (IND) Application OST-HER2 (Listeria monocytogenes) to OS Therapies in Record Time - Phase IIb Trial in Osteosarcoma in Early 2021